Literature DB >> 20479209

Mycobacterium tuberculosis and sulfamethoxazole susceptibility.

Wendy Ong, Aina Sievers, David E Leslie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20479209      PMCID： PMC2876382          DOI： 10.1128/AAC.00029-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  Tuberculosis and trimethoprim-sulfamethoxazole.

Authors:  Pierre Forgacs; Nancy L Wengenack; Leslie Hall; Sarah K Zimmerman; Mark L Silverman; Glenn D Roberts
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

2.  Combined antibacterial action in vitro of trimethoprim and sulphonamides. The in vitro nature of synergy.

Authors:  S R Bushby
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

3.  In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.

Authors:  R J Wallace; K Wiss; M B Bushby; D C Hollowell
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr
  3 in total
  16 in total

1.  para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.

Authors:  Jun Zheng; Eric J Rubin; Pablo Bifani; Vanessa Mathys; Vivian Lim; Melvin Au; Jichan Jang; Jiyoun Nam; Thomas Dick; John R Walker; Kevin Pethe; Luis R Camacho
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

2.  In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in France.

Authors:  Sirwan Muhammed Ameen; Michel Drancourt
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

3.  Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.

Authors:  Sam Ogwang; Caryn E Good; Brenda Okware; Mary Nsereko; Michael R Jacobs; W Henry Boom; Charles M Bark
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 4.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

5.  The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.

Authors:  Catherine Vilchèze; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

6.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

7.  Bacterial conversion of folinic acid is required for antifolate resistance.

Authors:  Sam Ogwang; Hoa T Nguyen; Marissa Sherman; Saralee Bajaksouzian; Michael R Jacobs; W Henry Boom; Guo-Fang Zhang; Liem Nguyen
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

8.  Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Authors:  N Alsaad; J A Dijkstra; O W Akkerman; W C M de Lange; D van Soolingen; J G W Kosterink; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

9.  Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.

Authors:  Barbara Hasse; A Sarah Walker; Jan Fehr; Hansjakob Furrer; Matthias Hoffmann; Manuel Battegay; Alexandra Calmy; Jacques Fellay; Caroline Di Benedetto; Rainer Weber; Bruno Ledergerber
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

Review 10.  Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.

Authors:  Kerstin A Wolff; Liem Nguyen
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.